Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance

Zhen Wang(Ministry of Education), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Xu‐Chao Zhang(Guangdong Academy of Medical Sciences), Jin‐Ji Yang(Guangdong General Hospital), Jie Huang(Sun Yat-sen University), Han Han‐Zhang(Burning Rock Biotech (China)), Junyi Ye(Burning Rock Biotech (China)), Hai‐Yan Tu(Jiangnan University)
Journal of Thoracic Oncology
June 27, 2017
10.1016/j.jtho.2017.06.017
Cited by 220

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k